|
| Clinical trial identifier | Drug | Mechanism | Status | Patient population | Phase |
|
| NCT02601937 | Tazemetostat (EPZ-6438) | Selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 | Recruiting | (i) Rhabdoid tumors; atypical teratoid rhabdoid tumor (ATRT); malignant rhabdoid tumor (MRT); rhabdoid tumor of kidney (RTK); selected tumors with rhabdoid features; INI1-negative tumors; epithelioid sarcoma; epithelioid malignant peripheral nerve sheath tumor; extraskeletal myxoid chondrosarcoma; myoepithelial carcinoma; renal medullary carcinoma; other INI1-negative malignant tumors (e.g., dedifferentiated chordoma); synovial sarcoma | I |
| NCT03165721 | Guadecitabine (SGI-110) | DNA methyltransferase inhibitor (DNMT1 inhibitor) | Completed | (i) Wild-type gastrointestinal stromal tumors; paraganglioma gastrointestinal stromal tumors; renal cell renal neoplasms; pheochromocytoma | II |
| NCT03600649 | SP-2577 | LSD1 inhibitor | Recruiting | (i) Relapsed or refractory Ewing sarcoma | I |
| NCT03514407 | INCB059872 | LSD1 inhibitor | Completed | (i) Relapsed Ewing sarcoma | I |
| NCT02282917 | AR-42(OSU-HDAC42) | Histone deacetylase inhibitor | Active, not recruiting | (i) Vestibular schwannoma; meningioma; acoustic neuroma; neurofibromatosis type 2 | 1 |
| NCT01175109 | Imatinib + LBH589 | LBH589, a histone deacetylase inhibitor | Completed | (i) Newly diagnosed and recurrent chordoma | I |
| NCT03345485 | Tinostamustine (EDO-S101) | First-in-class alkylating histone deacetylase inhibition (HDACi) fusion molecule | Active, not recruiting | (i) Small-cell lung cancer; soft-tissue sarcoma; triple-negative breast cancer; ovarian cancer; endometrial cancer | I/II |
| NCT00918489 | Vorinostat | Histone deacetylase inhibitor | Completed | (i) Metastatic soft-tissue sarcoma | II |
| NCT01294670 | Vorinostat and etoposide | Histone deacetylase inhibitor | Completed | (i) solid tumors; relapsed/refractory sarcomas | I/II |
| NCT04308330 | Vorinostat in combination with vincristine, irinotecan, and temozolomide | Histone deacetylase inhibitor | Recruiting | (i) Ewing sarcoma; rhabdomyosarcoma; Wilms tumor; neuroblastoma; hepatoblastoma; germ-cell tumor | I |
| NCT01879085 | Vorinostat in combination with gemcitabine and docetaxel | Histone deacetylase inhibitor | Recruiting | (i) Metastatic or locally advanced soft-tissue sarcoma | I/II |
| NCT01132911 | Vorinostat and bortezomib | Histone deacetylase inhibitor | Completed | (i) Lymphoma; sarcoma; Wilms tumor; neuroblastoma | I |
| NCT00937495 | Vorinostat and bortezomib | Histone deacetylase inhibitor | Completed | (i) Recurrent or advanced adult soft-tissue sarcoma | II |
|
